ARTICLES ON VALVULOPATHIES
Safe early discharge after TAVI: is it possible?
A retrospective observational study evaluating patients who underwent TAVI to identify predictive factors for atrioventricular block (AVB) within 24 hours to 30 days post procedure and to develop a risk stratification tool.
Tricuspid regurgitation: guidelines, definitions, and current treatment alternatives. An expert opinion.
Dr. Juan Diego Sánchez’s perspective on the current state of the art in tricuspid regurgitation treatment.
Long-term stroke and mortality risk in nonagenarians after TAVI: does it influence mortality?
This study provides increasingly necessary information to optimize decision-making in a population traditionally underrepresented in TAVI clinical trials: nonagenarian patients.
Success of Transatrial Transcatheter Mitral Valve Replacement in the Management of MAC in the United States
This retrospective study analyzes the outcomes and trends in the utilization of transatrial transcatheter mitral valve replacement (TA-TMVR) in high-risk patients with mitral annular calcification (MAC) between 2014 and 2021 in the U.S. population.
TAVI in bicuspid aortic valves: no matter how hard you try, it won’t turn round
Comparative study on the behavior of TAVI prostheses implanted in bicuspid and tricuspid aortic valves, focusing on deformation, development of paravalvular leakage, and thrombosis.
Between a rock and a hard place: bovine or porcine aortic bioprosthetic valves? Which is better?
A retrospective observational study comparing the clinical outcomes of aortic valve replacement using porcine and bovine pericardial bioprostheses, based on nationwide administrative databases in Korea between 2003 and 2018.
Low-dose anticoagulation in patients with On-X® aortic prosthesis: Increased safety without compromising efficacy
First results from a prospective, multicenter, single-arm registry clinical study aimed at evaluating the safety of low-dose warfarin anticoagulation combined with aspirin in patients undergoing isolated aortic valve replacement with the On-X® prosthesis (Artivion®) after 5 years of follow-up, comparing these results with the historical control group from the randomized PROACT clinical trial.
Poor TAVI outcomes in patients younger than 65: make AVR great again!
A propensity score-matched analysis of state health department registries from California, New York, and New Jersey comparing 6-year morbidity and mortality outcomes following TAVI or surgical aortic valve replacement in patients younger than 65 years.
Anticoagulation and TAVI: comparison of two strategies
A randomized noninferiority study comparing two perioperative anticoagulation strategies for TAVI.
COMMENCE at 7 years: Resilia tissue continues to perform well, though it is not infallible
This report details the 7-year outcomes of the COMMENCE study, which evaluates the results of aortic valve replacement using the Edwards Inspiris RESILIA® prosthesis.